Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02139, USA.
Department of Genetics, Yale University School of Medicine, New Haven, CT 06510, USA; Yale Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
Cell. 2020 May 14;181(4):832-847.e18. doi: 10.1016/j.cell.2020.03.062. Epub 2020 Apr 17.
Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well understood. Leveraging an autochthonous mouse model, we demonstrate a causal and reversible role for obesity in early PDAC progression, showing that obesity markedly enhances tumorigenesis, while genetic or dietary induction of weight loss intercepts cancer development. Molecular analyses of human and murine samples define microenvironmental consequences of obesity that foster tumorigenesis rather than new driver gene mutations, including significant pancreatic islet cell adaptation in obesity-associated tumors. Specifically, we identify aberrant beta cell expression of the peptide hormone cholecystokinin (Cck) in response to obesity and show that islet Cck promotes oncogenic Kras-driven pancreatic ductal tumorigenesis. Our studies argue that PDAC progression is driven by local obesity-associated changes in the tumor microenvironment and implicate endocrine-exocrine signaling beyond insulin in PDAC development.
肥胖是胰腺导管腺癌(PDAC)的一个主要可改变的风险因素,但肥胖如何以及何时促进 PDAC 的进展尚不清楚。利用一种自发的小鼠模型,我们证明了肥胖在早期 PDAC 进展中具有因果关系和可逆转的作用,表明肥胖显著增强了肿瘤发生,而遗传或饮食诱导的体重减轻则阻止了癌症的发展。对人和鼠样本的分子分析定义了肥胖促进肿瘤发生而不是新的驱动基因突变的微环境后果,包括肥胖相关肿瘤中胰腺胰岛细胞的显著适应性。具体来说,我们发现胆囊收缩素(CCK)这种肽激素在肥胖时异常表达于胰岛细胞,并表明胰岛 CCK 促进了致癌 Kras 驱动的胰腺导管肿瘤发生。我们的研究表明,PDAC 的进展是由肿瘤微环境中局部肥胖相关变化所驱动的,并暗示了内分泌-外分泌信号在 PDAC 发展中的作用超出了胰岛素。